BACKGROUND: Prospective characterization of hepatitis C virus (HCV) transmission in both human immunodeficiency virus (HIV)-infected and -uninfected men who have sex with men (MSM) over the entire HIV epidemic has not been comprehensively conducted. METHODS: To determine the trends in and risk factors associated with incident HCV in MSM since 1984, 5310 HCV antibody (anti-HCV)-negative MSM in the Multicenter AIDS Cohort Study were prospectively followed during 1984-2011 for anti-HCV seroconversion. RESULTS: During 55 343 person-years (PYs) of follow-up, there were 115 incident HCV infections (incidence rate, 2.08/1000 PYs) scattered throughout the study period. In a multivariable analysis with time-varying covariates, older age (incidence rate ratio [IRR], 1.40/10 years, P < .001), enrollment in the later (2001-2003) recruitment period (IRR, 3.80, P = .001), HIV infection (IRR, 5.98, P < .001), drinking >13 alcoholic drinks per week (IRR, 1.68, P < .001), hepatitis B surface antigen positivity (IRR, 1.68, P < .001), syphilis (IRR, 2.95, P < .001), and unprotected receptive anal intercourse with >1 male partner (IRR, 3.37, P < .001) were independently associated with incident HCV. Among HIV-infected subjects, every 100 cell/mm(3) increase in CD4 count was associated with a 7% (P = .002) decrease in the HCV incidence rate up to a CD4 count of 500 cells/mm(3), whereas there was no association with highly active antiretroviral therapy. CONCLUSIONS: The spread of HCV among both HIV-infected and -uninfected MSM in the United States has been ongoing since the beginning of the HIV epidemic. In HIV-infected men with <500 CD4(+) T cells, the HCV incidence rate was inversely proportional to CD4 T-cell count.
BACKGROUND: Prospective characterization of hepatitis C virus (HCV) transmission in both human immunodeficiency virus (HIV)-infected and -uninfected men who have sex with men (MSM) over the entire HIV epidemic has not been comprehensively conducted. METHODS: To determine the trends in and risk factors associated with incident HCV in MSM since 1984, 5310 HCV antibody (anti-HCV)-negative MSM in the Multicenter AIDS Cohort Study were prospectively followed during 1984-2011 for anti-HCV seroconversion. RESULTS: During 55 343 person-years (PYs) of follow-up, there were 115 incident HCV infections (incidence rate, 2.08/1000 PYs) scattered throughout the study period. In a multivariable analysis with time-varying covariates, older age (incidence rate ratio [IRR], 1.40/10 years, P < .001), enrollment in the later (2001-2003) recruitment period (IRR, 3.80, P = .001), HIV infection (IRR, 5.98, P < .001), drinking >13 alcoholic drinks per week (IRR, 1.68, P < .001), hepatitis B surface antigen positivity (IRR, 1.68, P < .001), syphilis (IRR, 2.95, P < .001), and unprotected receptive anal intercourse with >1 male partner (IRR, 3.37, P < .001) were independently associated with incident HCV. Among HIV-infected subjects, every 100 cell/mm(3) increase in CD4 count was associated with a 7% (P = .002) decrease in the HCV incidence rate up to a CD4 count of 500 cells/mm(3), whereas there was no association with highly active antiretroviral therapy. CONCLUSIONS: The spread of HCV among both HIV-infected and -uninfected MSM in the United States has been ongoing since the beginning of the HIV epidemic. In HIV-infectedmen with <500 CD4(+) T cells, the HCV incidence rate was inversely proportional to CD4 T-cell count.
Authors: J M Turner; A T Rider; J Imrie; A J Copas; S G Edwards; J P Dodds; J M Stephenson Journal: Sex Transm Infect Date: 2006-08 Impact factor: 3.519
Authors: Andri Rauch; Martin Rickenbach; Rainer Weber; Bernard Hirschel; Philip E Tarr; Heiner C Bucher; Pietro Vernazza; Enos Bernasconi; Annelies S Zinkernagel; John Evison; Hansjakob Furrer Journal: Clin Infect Dis Date: 2005-06-21 Impact factor: 9.079
Authors: R Detels; L Jacobson; J Margolick; O Martinez-Maza; A Muñoz; J Phair; C Rinaldo; S Wolinsky Journal: Public Health Date: 2011-12-27 Impact factor: 2.427
Authors: Thijs J W van de Laar; Akke K van der Bij; Maria Prins; Sylvia M Bruisten; Kees Brinkman; Thomas A Ruys; Jan T M van der Meer; Henry J C de Vries; Jan-Willem Mulder; Michiel van Agtmael; Suzanne Jurriaans; Katja C Wolthers; Roel A Coutinho Journal: J Infect Dis Date: 2007-06-11 Impact factor: 5.226
Authors: Mark Danta; David Brown; Sanjay Bhagani; Oliver G Pybus; Caroline A Sabin; Mark Nelson; Martin Fisher; Anne M Johnson; Geoffrey M Dusheiko Journal: AIDS Date: 2007-05-11 Impact factor: 4.177
Authors: Jannie J van der Helm; Maria Prins; Julia del Amo; Heiner C Bucher; Geneviève Chêne; Maria Dorrucci; John Gill; Osamah Hamouda; Mette Sannes; Kholoud Porter; Ronald B Geskus Journal: AIDS Date: 2011-05-15 Impact factor: 4.177
Authors: Taraz Samandari; Ellen Tedaldi; Carl Armon; Rachel Hart; Joan S Chmiel; John T Brooks; Kate Buchacz Journal: Open Forum Infect Dis Date: 2017-06-10 Impact factor: 3.835
Authors: Eric C Seaberg; Mallory D Witt; Lisa P Jacobson; Roger Detels; Charles R Rinaldo; Joseph B Margolick; Stephen Young; John P Phair; Chloe L Thio Journal: Clin Infect Dis Date: 2015-07-14 Impact factor: 9.079
Authors: Weiying Zhang; Tricia L Nilles; Jacquett R Johnson; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-22 Impact factor: 6.053
Authors: Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196